We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

INTC:NASDAQIntel Corporation Analysis

Data as of 2026-03-09 - not real-time

$45.58

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Intel’s stock is trading around the 20‑day simple moving average, just above the 50‑day average, while the 200‑day average remains well below current levels, indicating a short‑term price plateau. Technical momentum is mixed: the RSI sits near 50, suggesting no clear overbought or oversold condition, but the MACD line sits below its signal, producing a bearish histogram. Volatility is elevated, with a 30‑day price swing exceeding 60% and a beta of roughly 1.5, pointing to heightened sensitivity to market moves. Recent earnings missed expectations, triggering a 7‑plus percent slide and a shift toward negative sentiment, while AMD’s market share gains intensify competitive pressure. The DCF‑derived fair value of about $17 is far below the current price near $45, leading to an overvalued assessment. Moreover, the company carries a massive debt load (debt‑to‑equity > 30) and negative free cash flow, raising concerns about financial flexibility. On the upside, Intel is pursuing AI‑native and 6G collaborations and has secured a strategic partnership with Infosys, which could lay groundwork for longer‑term growth. However, bipartisan congressional scrutiny over chip‑making equipment adds a regulatory headwind that could affect future capital allocation.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD divergence
  • Recent earnings miss and price drop
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Mixed technical signals around moving averages
  • Ongoing competitive pressure from AMD
  • Uncertain cash flow generation

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic AI and 6G collaborations
  • Potential market share gains from new product road‑maps
  • Long‑term industry growth despite current valuation gap

Key Metrics & Analysis

Financial Health

Revenue Growth-4.10%
Profit Margin-0.51%
P/E Ratio46.0
ROE0.02%
ROA0.28%
Debt/Equity37.28
P/B Ratio2.0
Op. Cash Flow$9.7B
Free Cash Flow$-4504500224
Industry P/E36.9

Technical Analysis

TrendBullish
RSI50.0
Support$41.64
Resistance$51.22
MA 20$45.81
MA 50$45.22
MA 200$33.04
MACDBearish
VolumeStable
Fear & Greed Index100

Valuation

Fair Value$16.90
Target Price$47.11
Upside/Downside3.36%
GradeOvervalued
TypeValue

Risk Assessment

Beta1.55
Volatility63.17%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.